Press release
Epithelial Ovarian Cancer Market Size Forecasted To Achieve 4.41 Billion By 2029 With Steady Growth
Epithelial Ovarian Cancer
What Is the Epithelial Ovarian Cancer Market Size and Projected Growth Rate?
The market size for epithelial ovarian cancer has experienced swift expansion in the past few years. The market is projected to escalate from $2.08 billion in 2024 to $2.42 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 16.5%. Factors that have contributed to the growth during the historic period include an increased demand for personalized cancer therapies, an uptick in worldwide healthcare spending, a growing preference for minimally invasive surgical procedures, an increase in the number of ovarian cancer survivors, a surge in demand for gene therapies, and a rising demand for palliative care services.
The market size for epithelial ovarian cancer is predicted to expand quickly in the coming years, reaching $4.41 billion in 2029 with a compound annual growth rate (CAGR) of 16.1%. The anticipated growth within this forecast period can primarily be attributed to factors such as an increase in the number of ovarian cancer incidences, an older population, increasing levels of ovarian cancer awareness, a boost in cancer research funding, and inflating governmental efforts to fight cancer. Trends during this period are expected to include advancements in medical imaging technology, the launch of new molecular diagnostic tools, partnerships amongst pharmaceutical companies, swift adoption of AI and machine learning in diagnostic procedures, and a widening use of robotic surgeries.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20778
What Are the Major Segments in the Epithelial Ovarian Cancer Market?
The epithelial ovarian cancer market covered in this report is segmented -
1) By Type Of Treatment: Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Surgery
2) By Drug Class: Platinum-based Chemotherapy Drugs, Poly(ADP-ribose) Polymerase Inhibitors, Bevacizumab, Chemotherapeutic Agents
3) By Stage Of Cancer: Early Stage, Advanced Stage
4) By Diagnosis Method: Imaging, Biopsy, Blood Tests
5) By End User: Hospitals, Clinics, Diagnostic Laboratories
Subsegments:
1) By Chemotherapy: Platinum-Based Chemotherapy, Non-Platinum Chemotherapy, Combination Chemotherapy
2) By Targeted Therapy: Monoclonal Antibodies, PARP Inhibitors, Angiogenesis Inhibitors, Other Targeted Agents
3) By Immunotherapy: Checkpoint Inhibitors, Cancer Vaccines, Adoptive T-Cell Therapy
4) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Progestins
5) By Surgery: Debulking Surgery, Oophorectomy, Hysterectomy, Other Surgical Procedures
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20778&type=smp
What Are The Driving Epithelial Ovarian Cancer Market Evolution?
The epithelial ovarian cancer market's growth is anticipated to surge due to the rising prevalence of ovarian cancer. The primary contributors to the increasing cases of ovarian cancer, which primarily impacts the epithelial cells coating the ovaries' surface, are improved awareness, aging population, higher detection rates, and genetic and lifestyle elements. Treating epithelial ovarian cancer, the most common and aggressive variant of ovarian cancer, is crucial to target malignant cells and improve patient survival rates and outcomes. As noted by the World Ovarian Cancer Coalition, a non-profit organization based in Canada, in February 2024, the global count of women diagnosed with ovarian cancer is anticipated to surge over 55% by 2050, peaking at 503,448. It is also forecasted that the yearly ovarian cancer mortality rate will climb to 350,956, marking around a 70% increase from 2022. Thus, the proliferating prevalence of ovarian cancer will boost the epithelial ovarian cancer market in the future.
Which Firms Dominate The Epithelial Ovarian Cancer Market Segments?
Major companies operating in the epithelial ovarian cancer market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Merck KGaA, Siemens Healthineers AG, Quest Diagnostics Incorporated, Eisai Co. Ltd., Genentech Inc., Qiagen N.V., Myriad Genetics Inc., Zymeworks Inc., Novogen Limited, Karyopharm Therapeutics Inc., Clovis Oncology Inc., ImmunoGen Inc., Fujirebio Diagnostics Inc., Vivesto AB
What Trends Are Expected to Dominate the Acquired Autoimmune Hemolytic Anemia Market in the Next 5 Years?
Leading firms in the epithelial ovarian cancer market are concentrating on creating novel treatment solutions, for instance, FRα-directed antibody-drug conjugates (ADCs), that precisely attack the excess folate receptor-alpha (FRα) found in cancer cells, introducing powerful cytotoxic drugs while reducing damage to healthy tissue. FRα-directed ADC is a cancer treatment strategy that attaches an antibody, particular to the FRα, to a cytotoxic drug, transporting the drug straight to the cancer cells expressing this receptor. To illustrate, in November 2024, American biopharmaceutical organization, AbbVie Inc., secured European Commission endorsement for ELAHERE (mirvetuximab soravtansine), a treatment specifically aimed at adults with FRα positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. ELAHERE offers a fresh, potent treatment alternative for patients who have undergone up to three previous systemic regimens. It targets a biomarker observed in approximately one-third of ovarian cancer patients, boosting survival prospects and bettering life quality. This approval also encompasses a companion diagnostic to pinpoint appropriate patients.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/epithelial-ovarian-cancer-global-market-report
Which Is The Largest Region In The Epithelial Ovarian Cancer Market?
North America was the largest region in the epithelial ovarian cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epithelial ovarian cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Epithelial Ovarian Cancer Market?
2. What is the CAGR expected in the Epithelial Ovarian Cancer Market?
3. What Are the Key Innovations Transforming the Epithelial Ovarian Cancer Industry?
4. Which Region Is Leading the Epithelial Ovarian Cancer Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.
Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Epithelial Ovarian Cancer Market Size Forecasted To Achieve 4.41 Billion By 2029 With Steady Growth here
News-ID: 4067141 • Views: …
More Releases from The Business Research Company
Unlocking Opportunities in the Tyrosine Kinase Inhibitors Market: 2025-2034 Fore …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Tyrosine Kinase Inhibitors Industry Market Size Be by 2025?
The market for tyrosine kinase inhibitors has seen robust growth in recent times. The market is predicted to expand from $58.03 billion in 2024 to $62.66 billion in 2025, marking a compound annual growth rate (CAGR) of…
Sustained Release Excipients Market Advances With Product Innovation Industry Tr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Sustained Release Excipients Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, the market size of sustained release excipients has seen significant growth. It's projected to increase from $1.4 billion in 2024 to $1.51 billion in 2025, exhibiting a Compound Annual Growth Rate…
Surge In Cancer Cases Fuels Expansion Of The RNA-Targeting Small Molecule Therap …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the RNA Targeting Small Molecules Therapeutics Market Size By 2025?
In recent years, the market size of RNA targeting small molecules therapeutics has witnessed substantial growth. The market, which is estimated to be worth $6.1 billion in 2024, is projected to increase to $7.83 billion in…
Surge In Autoimmune Diseases Fuels Remicade Biosimilar Market Growth Emerges as …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Remicade Biosimilar Market Through 2025?
In recent times, we've seen significant expansion in the remicade biosimilar market. Projected growth from 2024's $3.95 billion to $4.89 billion in 2025 indicates a compound annual growth rate (CAGR) of 23.8%. This rise during the historic…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
